| Bioactivity | MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx[1]. | |||||||||
| Invitro | MLN3126 inhibits CCL25-induced calcium mobilization with an IC50 value of 6.3 nM in CCR9 expressing cells[1].MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50 of 14.2 nM[1]. Cell Invasion Assay[1] Cell Line: | |||||||||
| In Vivo | MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells[1].MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)[1]. Animal Model: | |||||||||
| Name | MLN3126 | |||||||||
| CAS | 628300-71-0 | |||||||||
| Formula | C21H19ClN2O5S | |||||||||
| Molar Mass | 446.90 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Igaki K, et al. MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model. Int Immunopharmacol. 2018 Jul;60:160-169. |
MLN3126
CAS: 628300-71-0 F: C21H19ClN2O5S W: 446.90
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotax
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.